PL438355A1 - Imidazolium salt being a lithocholic acid derivative, method of its preparation and its use - Google Patents

Imidazolium salt being a lithocholic acid derivative, method of its preparation and its use

Info

Publication number
PL438355A1
PL438355A1 PL438355A PL43835521A PL438355A1 PL 438355 A1 PL438355 A1 PL 438355A1 PL 438355 A PL438355 A PL 438355A PL 43835521 A PL43835521 A PL 43835521A PL 438355 A1 PL438355 A1 PL 438355A1
Authority
PL
Poland
Prior art keywords
sub
imidazolium salt
lithocholic acid
acid derivative
preparation
Prior art date
Application number
PL438355A
Other languages
Polish (pl)
Inventor
Diana SAWICKA
Agnieszka Hryniewicka
Halina CAR
Jacek MORZYCKI
Original Assignee
Uniwersytet Medyczny W Białymstoku
Uniwersytet W Białymstoku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny W Białymstoku, Uniwersytet W Białymstoku filed Critical Uniwersytet Medyczny W Białymstoku
Priority to PL438355A priority Critical patent/PL438355A1/en
Priority to EP22758011.5A priority patent/EP4366740A1/en
Priority to PCT/IB2022/056197 priority patent/WO2023281388A1/en
Publication of PL438355A1 publication Critical patent/PL438355A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Przedmiotem wynalazku jest sól imidazoliowa, będąca pochodną kwasu litocholowego, o wzorze strukturalnym 1: przy czym X jest wybrany z grupy obejmującej: I, Br, Cl, oraz R jest wybrany z grupy obejmującej nierozgałęzione i rozgałęzione grupy alkilowe: -CH<sub>3</sub>, -C<sub>2</sub>H<sub>5</sub>, -C<sub>3</sub>H<sub>8</sub>, -C<sub>4</sub>H<sub>9</sub>, -C<sub>5</sub>H<sub>11</sub>, -C<sub>6</sub>H<sub>13</sub>, -C<sub>7</sub>H<sub>15</sub>, -C<sub>8</sub>H<sub>17</sub>, -C<sub>12</sub>H<sub>25</sub>, -C<sub>16</sub>H<sub>33</sub>, do zastosowania w leczeniu nowotworu. Kolejnymi przedmiotami wynalazku są sól imidazoliowa, będąca pochodną kwasu litocholowego, o wzorze strukturalnym, przy czym X jest wybrany z grupy obejmującej: I, Br Cl, oraz R jest wybrany z grupy obejmującej nierozgałęzione i rozgałęzione grupy alkilowe: -C<sub>3</sub>H<sub>8</sub>, -C<sub>4</sub>H<sub>9</sub>, -C<sub>7</sub>H<sub>15</sub>, -C<sub>8</sub>H<sub>17</sub>, -C<sub>12</sub>H<sub>25</sub>, -C<sub>16</sub>H<sub>33</sub>, sposób wytwarzania soli imidazoliowej według wynalazku oraz jej zastosowanie jako lek.The subject of the invention is an imidazolium salt, which is a derivative of lithocholic acid, having the structural formula 1: wherein X is selected from the group consisting of: I, Br, Cl, and R is selected from the group consisting of unbranched and branched alkyl groups: -CH<sub>3 </sub>, -C<sub>2</sub>H<sub>5</sub>, -C<sub>3</sub>H<sub>8</sub>, -C<sub> 4</sub>H<sub>9</sub>, -C<sub>5</sub>H<sub>11</sub>, -C<sub>6</sub>H<sub>13 </sub>, -C<sub>7</sub>H<sub>15</sub>, -C<sub>8</sub>H<sub>17</sub>, -C<sub> 12</sub>H<sub>25</sub>, -C<sub>16</sub>H<sub>33</sub>, for use in the treatment of cancer. Further objects of the invention are the imidazolium salt, which is a lithocholic acid derivative, having the structural formula wherein X is selected from the group consisting of: I, BrCl, and R is selected from the group consisting of unbranched and branched alkyl groups: -C<sub>3< /sub>H<sub>8</sub>, -C<sub>4</sub>H<sub>9</sub>, -C<sub>7</sub>H<sub>15</ sub>, -C<sub>8</sub>H<sub>17</sub>, -C<sub>12</sub>H<sub>25</sub>, -C<sub>16< /sub>H<sub>33</sub>, a method for preparing the imidazolium salt of the invention and its use as a medicine.

PL438355A 2021-07-05 2021-07-05 Imidazolium salt being a lithocholic acid derivative, method of its preparation and its use PL438355A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL438355A PL438355A1 (en) 2021-07-05 2021-07-05 Imidazolium salt being a lithocholic acid derivative, method of its preparation and its use
EP22758011.5A EP4366740A1 (en) 2021-07-05 2022-07-05 Imidazolium salt, which is a derivative of lithocholic acid, a method of its preparation and its use
PCT/IB2022/056197 WO2023281388A1 (en) 2021-07-05 2022-07-05 Imidazolium salt, which is a derivative of lithocholic acid, a method of its preparation and its use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL438355A PL438355A1 (en) 2021-07-05 2021-07-05 Imidazolium salt being a lithocholic acid derivative, method of its preparation and its use

Publications (1)

Publication Number Publication Date
PL438355A1 true PL438355A1 (en) 2023-01-09

Family

ID=83005941

Family Applications (1)

Application Number Title Priority Date Filing Date
PL438355A PL438355A1 (en) 2021-07-05 2021-07-05 Imidazolium salt being a lithocholic acid derivative, method of its preparation and its use

Country Status (3)

Country Link
EP (1) EP4366740A1 (en)
PL (1) PL438355A1 (en)
WO (1) WO2023281388A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9072729B2 (en) * 2008-01-30 2015-07-07 Agency For Science, Technology And Research Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds
PL237764B1 (en) * 2018-06-28 2021-05-31 Univ W Bialymstoku Steroidal imidazolium salt, methods of its production and its applications

Also Published As

Publication number Publication date
EP4366740A1 (en) 2024-05-15
WO2023281388A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
ZA202409114B (en) MODULATORS OF THR-ß AND METHODS OF USE THEREOF
RU2495044C2 (en) Protein tyrosine kinase activity inhibitors
JOP20220069A1 (en) Bifunctional BRD9 proteolytic agents and methods for their use
EP4660303A3 (en) Pcsk9 antagonist compounds
SA523442662B1 (en) APOL1 inhibitors and their uses
EA201390840A1 (en) POLYCYCLIC LPAANTHAGONIST AND ITS APPLICATION
CR20240312A (en) Imidazole macrocycles for the treatment of autoimmune disease
GEAP202416543A (en) 4-phenyl-2-(1h-1,2,3-triazol-4-yl)piperidin-4-ol derivatives as inhibitors of apol1 and methods of using same
EA200870321A1 (en) Method of producing 4-oxyquinoline compound
MX389965B (en) Pyrrolopyridine-aniline compounds for treatment of dermal disorders
MX2021006544A (en) Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer.
MX2021012223A (en) Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease.
GEAP202516802A (en) Protac chimeric compound, preparation method thereof and use thereof
MX2019013562A (en) Fused heteroaromatic-aniline compounds for treatment of dermal disorders.
MX2022010957A (en) Compounds targeting rna-binding proteins or rna-modifying proteins.
EA201892460A1 (en) ADENIN DERIVATIVES AS PROTEINKINASE INHIBITORS
MX2025005209A (en) Lipid compounds and uses thereof
RU2014129937A (en) METHODS AND INTERMEDIATE COMPOUNDS FOR PRODUCING PHARMACEUTICAL AGENTS
PL438355A1 (en) Imidazolium salt being a lithocholic acid derivative, method of its preparation and its use
EA202091588A1 (en) METHOD FOR OBTAINING AMINOPYRIMIDINE AND ITS INTERMEDIATE PRODUCTS
WO2018109504A8 (en) N-oxide heterocycles for use in the treatment of cancer and bacterial diseases
CA3156457A1 (en) 1,8-NAPHTYRIDIN-2-ONE COMPOUNDS FOR THE TREATMENT OF AN AUTOIMMUNE DISEASE
EA200970745A1 (en) AZABICICOLALCANE DERIVATIVES, THEIR OBTAINING AND THEIR APPLICATION IN THERAPY
NZ600157A (en) Sustained-release formulation comprising metastin derivative
EA201100964A1 (en) PHENYLACYLAMIDAZOLISBOSPHOSPHONATES